TrialDiabetes, obesity & metabolism2025

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.

Matthew J Armstrong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.